The U.S. Food and Drug Administration approved AbbVie’s JUVMO (tavapadon) tablets for adults with Parkinson’s disease, including patients with early disease who are not taking oral levodopa and those experiencing motor fluctuations while using levodopa. AbbVie describes JUVMO as the first and only selective D1/D5 receptor agonist approved for the condition. The Phase 3 TEMPO program supported the decision, with TEMPO-3 showing that JUVMO plus levodopa increased daily "on" time without troublesome dyskinesia by 1.7 hours, compared with 0.6 hours for placebo plus levodopa. AbbVie expects U.S. availability in October 2026. The medicine has a list price of $4,900 per 30-day supply, or $58,800 annually. Analysts expect coverage to build gradually, with broad Medicare access unlikely until 2028 and initial access in 2026 and 2027 coming through formulary exceptions and appeals. William Blair estimates JUVMO sales could reach $1.4 billion in 2040, while AbbVie says its JUVMO, Vyalev and Duopa portfolio could generate at least $5 billion in peak sales. AbbVie shares were up 1.03% at $263.70 at the time of publication, near their 52-week high of $269.39.